Novo Nordisk has agreed to buy Emisphere Technologies for $1.8 billion, as it continues its quest to develop diabetes medicines that can be taken as pills.
Denmark’s Novo Nordisk has beaten profit forecasts in the second quarter after overcoming tough conditions in the diabetes market by improving its productivity.
Medical device company Indigo Diabetes has raised 38 million euros to develop an “invisible” sensor for people with diabetes, which could provide an alternative to the “patch” based monitor
AstraZeneca's Farxiga could be on course for another use, after trial results showed it slowed the worsening of renal function and cut the risk of death in patients with chronic kidney dise
Biocon has announced a deal with digital therapy specialist Voluntis, aiming to create personalised care for people with type 2 diabetes taking biosimilar insulins.